



NEWS RELEASE

Repligen to Present at the 25th Annual Piper Jaffray Healthcare Conference

2013-11-26

WALTHAM, Mass., Nov. 26, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present an overview of the Company at the 25th Annual Piper Jaffray Healthcare Conference on Tuesday, December 3 at 9:50 a.m. EST. The conference will be held December 3-4, 2013 at the New York Palace Hotel in New York.

A live audio webcast of the Repligen presentation will be accessible through the Investor Relations section of Company's website at www.repligen.com; see News & Events, Events & Presentations. This webcast will also be archived for a period of time on the Company's website.

About Repligen Corporation

Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are a leading manufacturer of Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. We also supply several growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, we have developed and market our OPUS® line of pre-packed "plug-and-play" chromatography columns used for biologics purification and we sell test kits to ensure final product quality. Repligen's corporate headquarters are located in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA and Lund, Sweden.

This press release may contain forward-looking statements within the meaning of the federal securities laws.

Investors are cautioned that statements in this press release which are not strictly historical statements including,

without limitation, statements identified by words like "believe," "expect," "may," "will," "should," "seek," or "could" and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements, except as required by law.

CONTACT: Sondra S. Newman
Director Investor Relations
snewman@repligen.com
(781) 419-1881

Source: Repligen Corporation